

Memorial Sloan Kettering Cancer Center
is pleased to announce:

Practical Management Strategies and New Innovations in Prostate Radiotherapy



*Featuring World Renowned
Speakers Covering
Cutting-Edge Topics*

Thursday-Friday
December 8-9, 2016

**CALL FOR
ABSTRACTS**

Conference Location:

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street New York, NY 10065



Memorial Sloan Kettering
Cancer Center



Course Overview

The course will include coverage of the following topics:

- Comparing outcomes for surgery and radiotherapy in clinically localized prostate cancer
- Optimal management strategies to treat acute and late side effects of radiotherapy
- Tips for reducing errors and improving QA for prostate Brachytherapy
- Updates on SBRT and Proton therapy in the treatment of prostate cancer
- Salvage radiotherapy after primary treatment failures and expected toxicity outcomes
- Optimal integration of hormonal therapy with prostate radiotherapy
- New developments in External Beam Treatment Planning including MR-Treatment Planning
- Guidelines for the Radiation Oncologist contouring target and nodal regions
- Integrating imaging into treatment selection and treatment planning

TARGET AUDIENCE

The target audience includes Radiation Oncologists, Urologists, Medical Oncologists, Medical Physicists, Radiation Therapists, Nurses and Residents.

CALL FOR ABSTRACTS

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. **The deadline for abstract submissions is 10/14/16.**

Visit the conference website for more information:

www.mskcc.org/radiotherapy.

Course Faculty


MSK COURSE DIRECTOR



Michael J. Zelefsky MD


Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service

MSK CO-COURSE DIRECTORS



Marisa A. Kollmeier MD

Radiation Oncologist, Attending



Sean McBride MD MPH

Radiation Oncologist, Attending

MSK FACULTY

Oguz Akin MD

Associate Attending Radiologist
Department of Radiology

Stefan Both PhD

Associate Attending Physicist
Department of Medical Physics

Oren Cahlon MD

Asst Attending Radiation Oncologist
Department of Radiation Oncology

Gilad Cohen MS

Senior Radiotherapy Physicist
Department of Medical Physics

Jonathan Coleman MD

Associate Attending Surgeon
Urology Service
Department of Surgery

James Eastham MD

Chief, Urology Service
Department of Surgery

Richard M. Gewanter MD

Asst Attending Radiation Oncologist
Commark/Rockville Center
Dept of Radiation Oncology

Laura Happersett MS

Senior Radiotherapy Physicist
Department of Medical Physics

Margie A. Hunt MS

Chief of Clinical Physics Service
Department of Medical Physics

Philip Kantoff MD

Chairman of Medicine
Department of Medical Oncology

James G. Mechalakos PhD

Section Head of External Beam Treatment
Department of Medical Physics

Michael J. Morris MD

Associate Attending Medical Oncologist
Department of Medical Oncology

John P. Mulhall MD

Attending Surgeon
Urology Service
Department of Surgery

Jaspreet S. Sandhu MD

Associate Attending Surgeon
Urology Service
Department of Surgery

Susan F. Slovin MD PhD

Attending Medical Oncologist
Department of Medical Oncology

Neelam Tyagi PhD

Assistant Attending Physicist
Department of Medical Physics

Herbert Alberto Vargas MD

Assistant Attending Radiologist
Department of Radiology

Wolfgang A. Weber MD

Chief of Molecular Imaging
and Therapy Service
Department of Radiology

INVITED FACULTY

Kristy Brock-Leatherman PhD

Assoc. Professor of Nuclear
Engineering & Radiological Sciences
Assoc. Professor of Radiation Oncology
University of Michigan
Ann Arbor, MI

Juanita Crook MD

Professor of Radiation Oncology
University of British Columbia
Vancouver, BC Canada

Anthony Victor D'Amico MD PhD

Professor of Radiation Oncology,
Harvard Medical School
Chief of Genitourinary Radiation Oncology,
Brigham and Women's Hospital
Boston, MA

Mark Emberton MD

Dean, Faculty of Medical Sciences
University College London Hospital
United Kingdom

Steven Jay Frank MD

Assoc Professor of Radiation Oncology
Deputy Department Chair, Strategic Programs
Proton Center Medical Director
MD Anderson Cancer Center
Houston, TX

Carri Glide-Hurst PhD

Senior Staff Physicist
Henry Ford Hospital
Detroit, MI

Carlo Greco MD

Director of Clinical Research
Champalimaud Centre for the Unknown
Lisbon, Portugal

Peter Hoskin MD

Consultant Clinical Oncologist
East and North Hertfordshire NHS Trust
United Kingdom

Patrick McLaughlin MD

Professor of Radiation Oncology
University of Michigan
Ann Arbor, MI

Jeff Michalski MD MBA

Professor of Radiation Oncology
Vice Chairman of Radiation Oncology
Chief of Genitourinary Service
Washington University in St. Louis
St. Louis, MO

Allan Pollack MD PhD

Chairman of Radiation Oncology
Professor of Radiation Oncology
University of Miami
Miami, FL

Mack Roach MD

Professor of Radiation Oncology and Urology
Director of Particle Therapy Research
Program & Outreach
Department of Radiation Oncology
UCSF Helen Diller Family
Comprehensive Cancer Center
San Francisco, CA

Howard Sandler MD MS

Chair in Cancer Therapeutics
Professor and Chair,
Department of Radiation Oncology
Cedars-Sinai Medical Center
Los Angeles, CA

Matthew Smith MD PhD

Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital
Cancer Center
Boston, MA

Robert Timmerman MD

Professor of Radiation Oncology
Neurological Surgery
UT Southwestern Medical Center
Dallas, TX

Anthony Laurence Zietman MD

Professor of Radiation Oncology
Director of GU Service
Massachusetts General Hospital
Boston, MA

Thursday, December 8, 2016

7:00-7:50 am

BREAKFAST & REGISTRATION

7:50-8:00 am

Welcome & Introduction

Michael J. Zelefsky MD

SESSION A:

Comparative Outcomes and Toxicity Management

8:00-9:15 am

Comparison of Outcomes and Toxicities and QOL between Treatment Interventions

MODERATOR Marisa A. Kollmeier MD

- **Comparison of Surgery and Radiotherapy for High Risk Disease: The Urologist's Perspective**
James Eastham MD
- **Comparison of Surgery, EBRT and Brachytherapy Based Modalities for High Risk Disease - The Radiation Oncologist Perspective**
Mack Roach MD
- **Comparison of Toxicity and QOL Outcomes between Surgery and Radiotherapeutic Interventions**
Jeff Michalski MD, MBA
- **Panel Discussion - Q&A**

9:15-10:30 am

Optimal Use of Androgen Deprivation Therapy (ADT) and Radiotherapy

MODERATOR Sean McBride MD, MPH

- **Optimal Duration of ADT for Intermediate and High Risk Disease**
Anthony Victor D'Amico MD, PhD
- **Managing the Side Effects of Prolonged ADT?**
Susan Slovin MD PhD
- **Maintaining Bone Health for the Patient Treated with ADT**
Matthew Smith MD, PhD
- **Panel Discussion and Q&A**

10:30-11:00 am

COFFEE BREAK

11:00-12:00 pm

Optimizing Management of Side Effects after EBRT and Brachytherapy

MODERATOR Michael J. Zelefsky MD

- **Addressing GI Toxicity**
Marisa A. Kollmeier MD
- **Addressing GU Toxicity**
Jaspreet S. Sandhu MD
- **Addressing Sexual Dysfunction**
John Mulhall MD
- **Panel Discussion and Q&A**

12:00-1:00 pm

Imaging for Prostate Cancer- Impact on Staging and Treatment Selection

MODERATOR Richard M. Gewanter MD

- **MP-MRI: Opportunities to Assess and Predict Treatment Response**
Herbert Alberto Vargas MD
- **Molecular Imaging and Novel Tracers in Prostate Cancer**
Wolfgang A. Weber MD
- **Putting It All Together: Using Imaging From Diagnosis to Treatment Assessment**
Steven Jay Frank MD
- **Panel Discussion and Q&A**

1:00-2:00 pm

LUNCH BREAK

SESSION B:

Radiotherapy Treatment Interventions: Technical Aspects

2:00-3:15 pm

Brachytherapy: Indications, Tumor Control Outcomes and Toxicity and Advances in the OR

MODERATOR Marisa Kollmeier MD

- **LDR-Indications, Relative Contraindications, and Where Are We in 2016**
Juanita Crook MD
- **HDR Indications, Relative Contraindications, and Where Are We in 2016**
Peter Hoskin MD
- **Advances in the Operating Room: Real Time Treatment Assessments and Imaged Based Fusions for Dose Intensification**
Michael J. Zelefsky MD
- **Optimal QA in the OR- Reducing Errors**
Gilad Cohen MS
- **Panel Discussion and Q&A**

3:15-4:15 pm

Structure Contouring: Basic Anatomy and What's New?

MODERATOR Sean McBride MD, MPH

- **MRI Anatomy of the Prostate and Critical Normal Tissues**
Patrick McLaughlin MD
- **Contouring the Pelvic Nodes with Confidence**
Oguz Akin MD
- **Multi-modality Image Registration and Fusion: Evaluating uncertainty and building confidence**
Kristy Brock-Leatherman PhD
- **Panel Discussion and Q&A**

4:15-4:30 pm

COFFEE BREAK

4:30-6:00 pm

Advances in External Beam Treatment Planning and Delivery

MODERATOR Neelam Tyagi PhD

- **Guidelines for Target and Normal Tissue Dose Constraints for EBRT and SBRT**
Laura Happersett MS
- **Refining the State-of-the-Art: Simulation through Treatment Planning: What are the New Treatment Planning Programs Able to Accomplish?**
James G. Mechalakos PhD
- **Advances in Multi-Modality Image-Based Planning and MR-Based Simulation**
Carri Glide-Hurst PhD
- **Treatment Delivery: Novel Approaches to Address Motion Reduction and Image Guidance**
Margie A. Hunt MS
- **Panel Discussion and Q&A**

6:00-6:45 pm

Cocktail Reception & Poster Presentations

Friday, December 9, 2016

7:30-8:00 am

BREAKFAST

SESSION C:

Novel Radiotherapy Treatment Interventions: Clinical Aspects

8:00-9:00 am

Department of Medicine Grand Rounds

Biomarkers and Genomics for Prostate Cancer
Philip Kantoff MD

9:15 10:30 am

SBRT Outcomes and Advances

MODERATOR Peter Hoskin MD

- **Tumor Control Outcomes and Toxicity for SBRT**
Michael J. Zelefsky MD
- **Moderate Hypofractionation**
Allan Pollack MD, PhD
- **High Dose Fractionated SBRT**
Robert Timmerman MD
- **Single Dose Radiotherapy for Localized Disease**
Carlo Greco MD
- **Panel Discussion and Q&A**

10:30-10:45 am

COFFEE BREAK

TO REGISTER TODAY, PLEASE VISIT:

www.mskcc.org/Radiotherapy



10:45-11:45 am

Proton Therapy: Is there an Established Role in the Treatment of Localized Disease?

MODERATOR Oren Cahlon MD

- **Clinical Outcomes & Toxicity and Tolerance Profiles and Comparison to Photon IMRT**
Anthony Laurence Zietman MD
- **Treatment Planning Challenges**
Stefan Both PhD
- **Cost Effectiveness of Protons versus Other Radiotherapeutic Interventions- Is there a Winner?**
Steven Jay Frank MD
- **Panel Discussion and Q&A**

11:45-1:00 pm

Improving Our Radiotherapy Outcomes for Intermediate and High Risk Prostate Cancer

MODERATOR Anthony Laurence Zietman MD

- **Important Considerations for Optimizing Outcomes for Local & Regional Therapy Using Radiotherapy in Intermediate and High Risk Disease**
Marisa A. Kollmeier MD
- **Elective Lymph Node Irradiation for Prostate Cancer: When, How and Is it Worth it?**
Mack Roach MD
- **Ongoing and Protocols in the Works for Prostate Cancer**
Howard Sandler MD, MS
- **Strategies Incorporating Targeted Therapy and Novel Anti-androgen and Radiotherapy**
Sean McBride MD, MPH
- **Panel Discussion and Q&A**

1:00-1:45 pm

LUNCH BREAK

SESSION D:

Salvage Therapy after Primary Treatment Failure

1:45-2:45 pm

Salvage Radiotherapy after Surgery

MODERATOR Howard Sandler MD, MS

- **Salvage versus Adjuvant Radiotherapy following Radical Prostatectomy**
Anthony Victor Damico MD, PhD
- **Optimal Contouring and Treatment planning considerations in the Salvage Setting**
Allan Pollack MD PhD
- **The Role of Hormonal Therapy in the Salvage Setting**
Anthony Laurence Zietman MD
- **Panel Discussion and Q&A**

2:45-3:45 pm

Salvage Options after RT failure

MODERATOR Michael J. Zelefsky MD

- **Outcomes with Brachytherapy as Salvage for Radio-Recurrent Disease**
Marisa A. Kollmeier MD
- **Outcomes of Surgery and Other Approaches in the Salvage Setting**
Jonathan Coleman MD
- **Focal Therapy Options and Outcomes**
Mark Emberton MD
- **Panel Discussion and Q&A**

3:45 pm

ADJOURN

Registration

REGISTRATION FEES	EARLY Before 10/8/16	GENERAL After 10/8/16
MDs, PhDs, DOs, and Medical Physicists	\$400	\$500
MSK Alliance and MSK Alumni	\$280	\$350
Residents, Fellows, RNs, Medical Students and other Healthcare Providers	\$150	\$250
Industry Members*	\$875	\$875

*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.

TO REGISTER TODAY, PLEASE VISIT:

www.mskcc.org/Radiotherapy

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the Continuing Medical Education page on [OneMSK](#).

CONTACT Continuing Medical Education
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th Floor New York, New York 10017
cme@mskcc.org

COURSE DESIGN

This course includes hands-on review of cases which will be intermixed with short didactic lectures.

EVALUATION

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

OUTCOMES MEASUREMENT SURVEY

Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

MSK designates this live activity for a maximum of **15.5 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for **15.5 AMA PRA Category 1 Credit(s)™**.

FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS

For information on hotels in the area of MSKCC with discounted rates, please visit: www.mskcc.org/accommodations.